Skip to main content
Zhejiang Yatai Pharmaceutical Co.,Ltd. logo

Zhejiang Yatai Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 002370 ISIN · CNE100000MM5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,986 across all filing types
Latest filing 2026-05-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002370

About Zhejiang Yatai Pharmaceutical Co.,Ltd.

https://www.ytyaoye.com

Zhejiang Yatai Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and distribution of a wide range of pharmaceutical products. The company's portfolio primarily focuses on anti-infective medications, including various cephalosporin and penicillin antibiotics. Additionally, it produces treatments for cardiovascular diseases, gastrointestinal disorders, and viral infections. Operating with a focus on both Active Pharmaceutical Ingredients (APIs) and finished preparations such as tablets, capsules, and lyophilized powder for injection, the firm maintains integrated production chains. The company emphasizes technological innovation and quality management systems to meet domestic and international standards. Its core operations encompass the full lifecycle of drug production, from chemical synthesis to large-scale commercial manufacturing, serving healthcare providers with essential therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于调整公司组织架构的公告
Board/Management Information Classification · 86% confidence The document is a corporate announcement of a board resolution (“第八届董事会第十三次会议审议通过了《关于调整公司组织架构的议案》”) to adjust the company’s internal organizational structure. It is not a financial report but a board/management announcement regarding governance and management. This fits the “Board/Management Information” category (MANG).
2026-05-29 Chinese
关于公司独立董事取得独立董事资格证书的公告
Board/Management Information Classification · 85% confidence The document is an official announcement by the company’s board regarding the election and qualification of a new independent director, detailing board composition changes. This fits the definition of a Board/Management Information filing.
2026-05-29 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 94% confidence The document is an official announcement of the 2025 shareholders’ meeting resolutions for Zhejiang Yatai Pharmaceutical Co., Ltd., detailing each proposal and the vote counts (agree, oppose, abstain) by shareholders and small investors. This matches the ‘Declaration of Voting Results & Voting Rights Announcements’ category (DVA).
2026-05-22 Chinese
君合律师事务所上海分所关于浙江亚太药业股份有限公司2025年度股东会之法律意见书
Regulatory Filings Classification · 80% confidence The document is a formal legal opinion letter (“法律意见书”) provided by JunHe Law Firm regarding the convening, voting procedures, and validity of the 2025 annual shareholders’ meeting for Zhejiang Yatai Pharmaceutical. It is not an actual financial report (10-K, IR, ER), nor an investor presentation, proxy statement, or voting result notice in a narrow sense. It is also not a certification or simple filing announcement but a substantive legal compliance opinion accompanying the meeting resolutions. There is no specific category for legal opinion letters outside of general regulatory compliance materials, so per the fallback rule it best fits into “Regulatory Filings” (RNS).
2026-05-22 Chinese
关于参加浙江辖区上市公司2026年投资者网上集体接待日暨2025年度业绩说明会的公告
Investor Presentation Classification · 85% confidence The document is an announcement from Zhejiang Yatai Pharmaceutical Co., Ltd. about its participation in an online investor collective reception day and a 2025 annual performance explanation meeting. It mentions the event date, participation details, and invites investors to submit questions in advance. The document does not contain actual financial statements or detailed financial data but rather serves as a notice about an upcoming investor presentation and interaction session. It is not the annual report itself, nor a transcript or earnings release. Given the nature of the content focusing on investor communication and company strategy discussion, this fits best as an Investor Presentation (IP) announcement or related material. However, since it is an announcement of participation in an investor event rather than the presentation itself, and it is relatively short, it aligns more closely with a Regulatory Filing (RNS) as a general announcement. But considering the detailed description of the investor meeting and the focus on performance explanation, the best fit is Investor Presentation (IP).
2026-05-07 Chinese
关于变更签字注册会计师的公告
Audit Report / Information Classification · 85% confidence The document is a public announcement by Zhejiang Asia-Pacific Pharmaceutical Co. about the change of the signing certified public accountants for its 2025 audit. This is not the full audit report, but an audit-related notice concerning auditor personnel. The most appropriate category is “Audit Report / Information” (AR), which covers standalone audit and audit-related announcements outside of full annual reports. FY 2025
2026-04-14 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.